Welcome to the Oyster Point Pharma Multimedia page.
Below, please find our downloadable assets and embed links for use by OysterPoint team members and healthcare professionals, subject to our terms of use.
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation.
Tyrvaya® (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.
Please click here for full Prescribing Information.
© 2023 Viatris Inc. and/or its affiliates. All rights reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company. Oyster Point®, the Oyster Point logo, Tyrvaya®, and the Tyrvaya logo are trademarks of Oyster Point Pharma, Inc., a Viatris company, in the United States and certain jurisdictions.
OP-TYR-002156